Liposcience Inc (LPDX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
2500 SUMNER BOULEVARD RALEIGH, NC 27616 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2014 MRQ | 12/31/2013 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 49,574 | |||
| Cash and cash equivalent | 49,574 | |||
| Receivables | 5,821 | |||
| Inventory, net of allowances, customer advances and progress billings | 224 | |||
| Inventory | 224 | |||
| Other undisclosed current assets | 972 | |||
| Total current assets: | 56,591 | |||
| Noncurrent Assets | ||||
| Property, plant and equipment | 13,955 | |||
| Intangible assets, net (including goodwill) | 841 | |||
| Intangible assets, net (excluding goodwill) | 841 | |||
| Restricted cash and investments | 502 | |||
| Deferred costs | 64 | |||
| Other noncurrent assets | 45 | |||
| Total noncurrent assets: | 15,407 | |||
| TOTAL ASSETS: | 71,998 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 2,045 | |||
| Accounts payable | 2,045 | |||
| Other undisclosed current liabilities | 19,560 | |||
| Total current liabilities: | 21,605 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 2,635 | |||
| Other liabilities | 2,635 | |||
| Total noncurrent liabilities: | 2,635 | |||
| Total liabilities: | 24,240 | |||
| Equity | ||||
| Equity, attributable to parent | 47,758 | |||
| Common stock | 15 | |||
| Additional paid in capital | 108,271 | |||
| Accumulated deficit | (60,528) | |||
| Total equity: | 47,758 | |||
| TOTAL LIABILITIES AND EQUITY: | 71,998 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2014 TTM | 12/31/2013 | ||
|---|---|---|---|
| Revenues (Revenue, Net) | 52,383 | ||
| Cost of revenue (Cost of Product and Service Sold) | (12,042) | ||
| Other undisclosed gross profit | 1,300 | ||
| Gross profit: | 41,641 | ||
| Operating expenses | (52,321) | ||
| Operating loss: | (10,680) | ||
| Nonoperating income | 87 | ||
| Investment income, nonoperating | 93 | ||
| Interest and debt expense | (1,942) | ||
| Loss from continuing operations: | (12,535) | ||
| Loss before gain (loss) on sale of properties: | (12,535) | ||
| Net loss available to common stockholders, diluted: | (12,535) | ||
Comprehensive Income ($ in thousands)
| 9/30/2014 TTM | 12/31/2013 | ||
|---|---|---|---|
| Net loss: | (12,535) | ||
| Comprehensive loss, net of tax, attributable to parent: | (12,535) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.